Publicaciones recientes

  1. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Lleó, A, Alcolea, D, Martínez-Lage, P et al. Alzheimers Dement 2019
    PMID:30967340

  2. Nanoscale structure of amyloid-β plaques in Alzheimer's disease. Querol-Vilaseca, M, Colom-Cadena, M, Pegueroles, J et al. Sci Rep 2019
    PMID:30914681

  3. The Epistasis Project: A Multi-Cohort Study of the Effects of BDNF, DBH, and SORT1 Epistasis on Alzheimer's Disease Risk. Belbin, O, Morgan, K, Medway, C et al. J. Alzheimers Dis. 2019
    PMID:30909233

  4. Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Illán-Gala, I, Montal, V, Borrego-Écija, S et al. Brain 2019
    PMID:30906945

  5. Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. Lleó, A, Parnetti, L, Belbin, O et al. Clin. Chim. Acta 2019
    PMID:30682327

  6. Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. Lleó, A, Núñez-Llaves, R, Alcolea, D et al. Mol. Cell Proteomics 2019
    PMID:30606734

  7. Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. Delaby, C, Muñoz, L, Torres, S et al. Clin. Chim. Acta 2019
    PMID:30579960

  8. Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. Pegueroles, J, Jiménez, A, Vilaplana, E et al. Oncotarget 2018
    PMID:30410669

  9. Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. Giménez, S, Videla, L, Romero, S et al. J Clin Sleep Med 2018
    PMID:30353801

  10. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. Alcolea, D, Irwin, DJ, Illán-Gala, I et al. J. Neurol. Neurosurg. Psychiatry 2019
    PMID:30297518

  11. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum. Illán-Gala, I, Alcolea, D, Montal, V et al. Neurology 2018
    PMID:30291183

  12. Challenges associated with biomarker-based classification systems for Alzheimer's disease. Illán-Gala, I, Pegueroles, J, Montal, V et al. Alzheimers Dement (Amst) 2018
    PMID:30175226

  13. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Fortea, J, Carmona-Iragui, M, Benejam, B et al. Lancet Neurol 2018
    PMID:30172624

  14. Strategies for Continued Successful Treatment in Patients with Alzheimer's Disease: An Overview of Switching Between Pharmacological Agents. Blesa, R, Toriyama, K, Ueda, K et al. Curr Alzheimer Res 2018
    PMID:29895249

  15. Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. Morenas-Rodríguez, E, Sala, I, Subirana, A et al. J. Alzheimers Dis. 2018
    PMID:29889064

  16. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. Lleó, A, Irwin, DJ, Illán-Gala, I et al. JAMA Neurol 2018
    PMID:29554190

  17. Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. Cantero, JL, Atienza, M, Sanchez-Juan, P et al. Neurobiol. Aging 2018
    PMID:29331877

  18. Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. Jimenez, A, Pegueroles, J, Carmona-Iragui, M et al. Oncotarget 2017
    PMID:29285207

  19. Alzheimer's disease: An ignored condition. Lleó, A Med Clin (Barc) 2018
    PMID:29196039

  20. Synaptic phosphorylated α-synuclein in dementia with Lewy bodies. Colom-Cadena, M, Pegueroles, J, Herrmann, AG et al. Brain 2017
    PMID:29177427

  21. Cortical microstructural changes along the Alzheimer's disease continuum. Montal, V, Vilaplana, E, Alcolea, D et al. Alzheimers Dement 2018
    PMID:29080407

  22. Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation. Dols-Icardo, O, García-Redondo, A, Rojas-García, R et al. J. Neurol. Neurosurg. Psychiatry 2018
    PMID:28889094

  23. The pitfalls of biomarker-based classification schemes. Illán-Gala, I, Vilaplana, E, Pegueroles, J et al. Alzheimers Dement 2017
    PMID:28704640

  24. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. Querol-Vilaseca, M, Colom-Cadena, M, Pegueroles, J et al. J Neuroinflammation 2017
    PMID:28599675

  25. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Alcolea, D, Vilaplana, E, Suárez-Calvet, M et al. Neurology 2017
    PMID:28592456

Lista completa